• Contact Us

  • Pipeline
    NM002 (Nylexa®) for COVID 19 NM002 (Nylexa®) for AMR NM001 (Lynovex®) NP339 for Invasive Fungal Disease NP339 for Respiratory Fungal Disease NP213 (Novexatin®)) NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • Therapeutic Focus
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Technology
  • Pipeline
    • NM002 (Nylexa®) for COVID19
    • NM002 (Nylexa®) for AMR
    • NM001 (Lynovex®)
    • NP339 for Invasive Fungal Disease
    • NP339 for Respiratory Fungal Disease
    • NP213 (Novexatin®)
    • NP432
  • Contact Us

News and Events

Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news

Mar 30, 2021

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Feb 26, 2021

NovaBiotics Attending BIO CEO & Investor Digital Conference

Feb 2, 2021

Just when we thought things were getting better…..

Dec 31, 2020

CARE CF 1 oral Lynovex clinical trial data published

Dec 29, 2020

NovaBiotics in the press

Dec 28, 2020

As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation

Nov 18, 2020

Why, in the current crisis we still need more effective, proven treatments for COVID-19

Nov 17, 2020

Appointment of Dr Malcolm Barratt-Johnson to the Board of NovaBiotics

Nov 10, 2020

The truth about why we need this COVID-19 treatment right now!

Oct 22, 2020

Categories

Press Releases

Events

Archives

2020 

2019

NovaBiotics Ltd
Silverburn Crescent
Bridge of Don
Aberdeen
AB23 8EW, UK

Tel:+44 (0)1224 711377

Registered Company
No. SC272344

NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108

Tel:+1 866 259 4527

NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9

Tel:+353 1 2712605

Registered Company
No. 642058

News and Events

About Us

Therapeutic Focus

Technology

Pipeline

Contact Us